Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.
Related news for (SEER)
- Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
- Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
- SpaceWorks Enterprises Inc. Integrates AI into Spaceflight Planning and National Defense Initiatives with SEERai, Galorath’s AI-Powered Cost Estimation Platform
- Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
- SEER LAUNCHES CARBON FOCUSED DIVISION TO PRODUCE LICENSED BIOCHAR, MONETIZE AND TOKENIZE ASSETS AND CARBON CREDITS AND DEVELOP TURBINE BLADE TREATMENT TECHNOLOGY